Table 1.
Patient and primary tumor characteristics at time of primary surgery for all patients who underwent mastectomy (n = 1571) as well as those who ultimately recurred post-mastectomy (n = 26).
| Characteristic | All Mastectomy Patients (n = 1571) | Patients with Chest Wall Recurrence (n = 26) |
|---|---|---|
| Age (years)* - Mean ± SD | 53 ± 13.0 | 58.0 ± 16.4 |
| Tumor stage* | ||
| T0 | 11 (0.8%) | 1 (3.8%) |
| T1 | 494 (31.4%) | 8 (30.8%) |
| T2 | 546 (34.8%) | 11 (42.3%) |
| T3 | 90 (5.7%) | 6 (23.1%) |
| T4 | 114 (37%) | 0 |
| Regional Lymph Nodes (N Stage) | ||
| N0 | 798 (50.8%) | 9 (34.6%) |
| N1 | 330 (21%) | 10 (38.4%) |
| N2 | 107 (6.8%) | 3 (11.5%) |
| N3 | 42 (2.7%) | 4 (15.4%) |
| Radiotherapy | ||
| Yes | 620 (39.5%) | 12 (46.2%) |
| No | 971 (60.5%) | 14 (53.8%) |
| Radiotherapy Boost to Chest Wall** | ||
| Yes | 395 (63.7%) | 11 (91.7%) |
| No | 225 (36.3%) | 1 (8.3%) |
| Radiotherapy Bolus to Mastectomy Flap** | ||
| Yes | 223 (36%) | 4 (33.3%) |
| No | 397 (64%) | 8 (66.7%) |
| Radiotherapy to Axilla** | ||
| Yes | 431 (69.5%) | 5 (41.7%) |
| No | 189 (30.5%) | 7 (58.3%) |
| Chemotherapy | ||
| Yes | 724 (46.1%) | 3 (11.5%) |
| No | 847 (53.9% | 23 (88.5%) |
| Molecular Subtype Classification | ||
| Luminal A | 766 (48.8%) | 10 (38.5%) |
| Luminal B | 352 (21.8%) | 6 (23.1%) |
| Triple Negative | 157 (10.0%) | 6 (23.1%) |
| HER2/neu+ | 417 (26.5%) | 4 (15.4%) |
| Clinical factors | ||
| Size of recurrence (cm) – Mean ± SD | n/a | 2.9 ± 2.4 |
| Time to recurrence (years)*** – Mean ± SD | n/a | 1.9 ± 1.6 |
*At time of mastectomy.
**Calculated as a percentage of the patients who received radiation.
**From date of mastectomy.